JPH0337709B2 - - Google Patents
Info
- Publication number
- JPH0337709B2 JPH0337709B2 JP15127582A JP15127582A JPH0337709B2 JP H0337709 B2 JPH0337709 B2 JP H0337709B2 JP 15127582 A JP15127582 A JP 15127582A JP 15127582 A JP15127582 A JP 15127582A JP H0337709 B2 JPH0337709 B2 JP H0337709B2
- Authority
- JP
- Japan
- Prior art keywords
- liver
- peaks
- present
- liquid chromatography
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 208000019423 liver disease Diseases 0.000 claims description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 238000004811 liquid chromatography Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000306 component Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 208000019425 cirrhosis of liver Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 8
- 208000006454 hepatitis Diseases 0.000 description 8
- 230000007170 pathology Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000012742 biochemical analysis Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 238000010876 biochemical test Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 206010008635 Cholestasis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 231100000354 acute hepatitis Toxicity 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 231100000359 cholestasis Toxicity 0.000 description 3
- 230000007870 cholestasis Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 2
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- -1 silane compound Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000016332 liver symptom Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000003969 polarography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15127582A JPS5940254A (ja) | 1982-08-31 | 1982-08-31 | 生体試料の分析方法 |
| CA000433955A CA1220700A (en) | 1982-08-06 | 1983-08-05 | Aqueous solution as an eluant used in liquid chromatography |
| DE8383304555T DE3374604D1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| EP83304555A EP0102769B1 (en) | 1982-08-06 | 1983-08-05 | Eluent for liquid chromatography |
| US06/795,275 US4666861A (en) | 1982-08-06 | 1985-11-05 | Aqueous solution as an eluent used in liquid chromatography |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15127582A JPS5940254A (ja) | 1982-08-31 | 1982-08-31 | 生体試料の分析方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5940254A JPS5940254A (ja) | 1984-03-05 |
| JPH0337709B2 true JPH0337709B2 (enrdf_load_stackoverflow) | 1991-06-06 |
Family
ID=15515111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15127582A Granted JPS5940254A (ja) | 1982-08-06 | 1982-08-31 | 生体試料の分析方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5940254A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63205565A (ja) * | 1987-02-20 | 1988-08-25 | Toshihito Hiraoka | 肝機能検査方法 |
-
1982
- 1982-08-31 JP JP15127582A patent/JPS5940254A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5940254A (ja) | 1984-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marsilio et al. | Simultaneous HPLC determination with light-scattering detection of lactulose and mannitol in studies of intestinal permeability in pediatrics | |
| Yatscoff et al. | Quantification of nonenzymically glycated albumin and total serum protein by affinity chromatography. | |
| CN113176411B (zh) | 利用唾液检测新型冠状病毒感染的生物标志物及其应用 | |
| André et al. | Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury | |
| Li et al. | Urinary kidney injury molecule‑1 as an early indicator to predict contrast‑induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention | |
| JP4516124B2 (ja) | 肝線維症の診断方法 | |
| Xue et al. | Urine biomarkers can outperform serum biomarkers in certain diseases | |
| Preeti et al. | Estimation of serum creatinine by routine Jaffé’s method and by dry chemistry in icteric and hemolytic serum samples | |
| CN112639476A (zh) | 肾病变蛋白生物标记及其应用 | |
| JP2004501366A (ja) | 患者の全血、血漿および（または）血清中のアルファ・オキソアルデヒドを検出する方法 | |
| JPH0337709B2 (enrdf_load_stackoverflow) | ||
| JPH0337708B2 (enrdf_load_stackoverflow) | ||
| Mohammed et al. | Evaluation of serum cystatin C as an early marker of renal disease in Chronic Kidney Disease patients in Kano | |
| CN118897083A (zh) | 尿液mt蛋白及其多肽片段在痛风中的应用 | |
| JPS5992349A (ja) | 生体試料の分析法 | |
| JPH0337710B2 (enrdf_load_stackoverflow) | ||
| RU2069857C1 (ru) | Способ определения степени поражения почек при нефротическом синдроме | |
| RU2220755C1 (ru) | Способ разделения смеси жирных кислот фракции c2-c6 методом газожидкостной хроматографии | |
| Liu et al. | Early Diagnostic Value of KIM‐1, NGAL, and NLR in Acute Kidney Injury Caused by Diquat Poisoning | |
| Severini et al. | Liquid-chromatographic determination of inosine, xanthine, and hypoxanthine in uremic patients receiving hemodialysis treatment. | |
| RU2666948C1 (ru) | Способ диагностики мочекаменной болезни | |
| Kalani et al. | Wilms’ tumor 1 in urinary exosomes as a non-invasive biomarker for diabetic nephropathy | |
| JP3664278B2 (ja) | 血漿または血清試料の調製方法 | |
| EP0102769B1 (en) | Eluent for liquid chromatography | |
| CN106187853A (zh) | 一种化合物及其制备方法和应用 |